Novel high –risk acute myeloid leukemia subgroup with ERG amplification and Biallelic loss of TP53

Acute myeloid leukemia (AML) is a heterogeneous disease with the most recent WHO classification [1] describing 11 subtypes with recurrent genetic abnormalities and>20 subtypes defined morphologically. Each genetically defined AML has specific findings that allow for appropriate risk-stratification and, for some, treatment selection. Apart from acute promyelocytic leukemia with PML:RARA fusion, AML induction therapy is not typically determined by genetics; however, the decision to pursue post-induction stem cell transplant has relied on clinical and genetic factors.

Source: Cancer Genetics and Cytogenetics - January 17, 2023 Category: Genetics & Stem Cells Authors: Cynthia A. Schandl, Sandra Mazzoni, Iya Znoyko, Georges J. Nahhas, Dongjun Chung, Yanna Ding, Brian Hess, Daynna J. Wolff Source Type: research